<?xml version="1.0" encoding="UTF-8"?>
<p>AAV2‐vectors transencapsidated into AAV9 capsids were produced, and integrity and identity of the AAV9 capsids were verified using the conformational capsid antibody ADK9 (
 <xref rid="emmm201910938-sup-0001" ref-type="supplementary-material">Appendix Fig S1C and D</xref>; Sonntag 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0075" ref-type="ref">2011</xref>). All vector stocks contained high amounts of encapsidated viral genomes (vg) and relatively low amounts of empty capsids (
 <xref rid="emmm201910938-sup-0001" ref-type="supplementary-material">Appendix Fig S1E and F</xref>). Correspondingly, robust 
 <italic>in vitro</italic> AAV vector transduction rates were achieved (Fig 
 <xref rid="emmm201910938-fig-0001" ref-type="fig">1</xref>D and 
 <xref rid="emmm201910938-sup-0001" ref-type="supplementary-material">Appendix Fig S1G</xref>).
</p>
